Over the last few years, very-low-b

Over the last few years, very-low-birthweight
(VLBW) infants below 1500 g often received dexamethasone
prophylactically to avoid development
of chronic lung disease. Several randomised studies
had shown that dexamethasone improved lung
function and reduced length of ventilation and need
for oxygen [1—3]. Short-term adverse effects of
dexamethasone therapy included hyperglycemia,
hypertension, cardiac hypertrophy, gastrointestinal
bleeding, sepsis, osteopenia, and growth retardation
[4,5]. These adverse effects were usually
transient and tolerated because the benefit of
improving the respiratory situation seemed to be
more important for long-term outcome.

ผลลัพธ์ (อังกฤษ) 2:

Over the last few years, very-low-birthweight
(VLBW) Infants Below 1500th G often received dexamethasone
prophylactically to Avoid Development
of Lung chronic disease. Several randomized Studies
had shown that dexamethasone improved Lung
function and reduced Ventilation and Length of Need
for Oxygen [1-3]. Short-term adverse effects of
dexamethasone included Hyperglycemia Therapy,
hypertension, cardiac hypertrophy, gastrointestinal
bleeding, sepsis, osteopenia, and growth retardation
[4,5]. These adverse effects were usually
transient and tolerated because the Benefit of
Improving the respiratory situation seemed to be
more important for long-term outcome.